Laboratory News and Research

RSS

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the twelve months ended December 31, 2009, and affirmed its 2010 milestones of commencing up to five Phase 2 clinical trials with its oncology drug candidates.

15 Mar 2010

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

Enzo Biochem, Inc. today announced that it has entered into an agreement with MultiGEN Diagnostics Inc., of San Diego, California, for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York. In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for its first quarter ended January 31, 2010. All amounts are in U.S. dollars unless otherwise indicated.

15 Mar 2010

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Cost-effective technology that allows products to be traced through the U.S. supply chain might have helped contain the spread of hydrolyzed vegetable protein products contaminated with Salmonella, Intelligent Global Pooling Systems announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending to overhaul the nation's food safety law.

15 Mar 2010

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Scientists in Texas are reporting development of a first-of-its-kind cloth that releases nitric oxide gas - an advance toward making therapeutic socks for people with diabetes and a wrap to help preserve organs harvested for transplantation. The study is in ACS' Chemistry of Materials, a bi-weekly journal.

15 Mar 2010

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented data today at the American College of Cardiology annual scientific sessions from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy) demonstrating the MitraClip, a novel, first-in-class catheter-based device, is a safe and effective alternative to open heart surgery for select patients with mitral regurgitation.

15 Mar 2010

ATS releases new clinical policy statement on CCHS

The American Thoracic Society has released a new official clinical policy statement on congenital central hypoventilation syndrome (CCHS), a disorder of respiratory and autonomic nervous system (ANS) regulation. The ANS regulates reflexive acts, including heart rate and blood pressure, digestion, body temperature and pain perception.

15 Mar 2010

Study: Chromosomal microarray analysis detects genetic changes related to ASDs better than standard tests

A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about three times the detection rate for genetic changes related to autism spectrum disorders (ASDs) than standard tests. Publishing in the April issue of Pediatrics (and online March 15), the authors urge that CMA become part of the first-line genetic work-up for ASDs.

15 Mar 2010

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well. The study was conducted to determine if immunized children could act as a barrier to limit the spread of influenza to the wider, unvaccinated community, a concept known as herd immunity.

15 Mar 2010

Researchers develop Intermountain Risk Score tool to assess patients' health

Researchers from the Heart Institute at Intermountain Medical Center in Murray, Utah, have devised a better way to determine an individual's risk for problems, such as heart attack and heart failure, according to a new study.

15 Mar 2010

New laboratory technique may help prioritize cancer drugs for clinical trials

Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells.

15 Mar 2010

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported today (15 March) in the Biochemical Journal.

15 Mar 2010

Painful periods at early age doubles risk of endometriosis

Queensland Institute of Medical Research scientists have identified a new link between strong period pain experienced in adolescence and early adulthood and the risk of endometriosis.

15 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

Two controlled environmental variables to preclinical mice tests can reduce costly false positives: Study

For decades, the traditional practice in animal testing has been standardization, but a study involving Purdue University has shown that adding as few as two controlled environmental variables to preclinical mice tests can greatly reduce costly false positives, the number of animals needed for testing and the cost of pharmaceutical trials.

15 Mar 2010

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

Increasing calcium intake is a common--yet not always successful--strategy for reducing bone fractures. But a study supported in part by the Agricultural Research Service (ARS) underscores the importance of vitamin D and its ability to help the body utilize calcium. The study also may explain why increasing calcium alone isn't always successful in dealing with this problem.

12 Mar 2010

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

InDevR, developer of advanced life science products, announced that its ampliPHOX Colorimetric Detection Technology is being beta site-tested in anticipation of an upcoming product launch. The original intellectual property was licensed from the University of Colorado at Boulder.

12 Mar 2010

Frontier Global Sciences awarded the Apex of laboratory accreditations: ISO 17025

Frontier Global Sciences (formerly Frontier GeoSciences), an internationally recognized leader in the testing of heavy metals, announced today it was awarded what is considered the Apex of laboratory accreditations: ISO 17025.

12 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

Laboratory News and Research

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Enzo Biochem to market MultiGEN’s multiplex DNA sequencing based diagnostic tests in state of New York

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Scientists develop nitric oxide-releasing cloth to make therapeutic socks for diabetes patients

Mitral regurgitation: MitraClip safe, effective alternative option to open heart surgery

ATS releases new clinical policy statement on CCHS

Study: Chromosomal microarray analysis detects genetic changes related to ASDs better than standard tests

Immunizing children against seasonal influenza can protect unvaccinated community against influenza

Researchers develop Intermountain Risk Score tool to assess patients' health

New laboratory technique may help prioritize cancer drugs for clinical trials

New findings shed light on how genetic damage to muscle cell proteins can lead to nemaline myopathy

Painful periods at early age doubles risk of endometriosis

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Two controlled environmental variables to preclinical mice tests can reduce costly false positives: Study

ARS study underlines the importance of vitamin D and its ability to help body utilize calcium

ampliPHOX detection technology of InDevR in beta site-testing in anticipation of upcoming product launch

Frontier Global Sciences awarded the Apex of laboratory accreditations: ISO 17025

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

A guide to density measurement excellence eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo